ADMA Biologics Inc (ADMA)
NASDAQ: ADMAHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 10.14 0.00%
ADMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.27B
- P/E (TTM)
- 14.49
- Forward P/E
- 10.75
- EPS (TTM)
- $0.70
- Dividend yield
- None
- 52-week range
- 7.21 – 20.46
- Day range
- 10.07 – 10.31
- Volume / Avg
- 3.05M / 2.62M
- Beta
- —
- Shares outstanding
- 223.98M
- Next earnings
- Nov 4, 2026
52-week range
ADMA stock today
On Oct 7, ADMA ended the session at $10.14, shedding $0.04 (0.39%), versus the S&P 500's 0.22% decline. Shares are 50.4% below their 52-week high of $20.46, set on Dec 12, 2025 and 40.6% above the 52-week low of $7.21, in the middle of the past year's range. ADMA is down 44.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 27.5%.
ADMA Biologics trades at 14.5x its trailing twelve-month earnings per share of $0.70. Its forward P/E of 10.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. ADMA Biologics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About ADMA Biologics
Company profileADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Adam S. Grossman
- Headquarters
- Ramsey, NJ
- Employees
- 640
- Website
- admabiologics.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$17.00+67.65%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.19
ADMA Biologics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs ADMA |
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs ADMA |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs ADMA |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs ADMA |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs ADMA |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs ADMA |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs ADMA |
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs ADMA |
Indexes, lists and sector
Appears in lists
ADMA Biologics stock FAQ
What is ADMA Biologics's stock price today?
ADMA last traded at $10.14 as of Oct 7, 4:00 PM EDT, down 0.39% on the day. Prices are delayed at least 15 minutes.
When is ADMA Biologics's next earnings date?
ADMA Biologics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.19.
What is ADMA's P/E ratio?
ADMA trades at a trailing P/E ratio of 14.49 and a forward P/E of 10.75.
Who is ADMA Biologics's CEO?
Mr. Adam S. Grossman is the chief executive officer of ADMA Biologics Inc, which has about 640 employees.
What is the ADMA 52-week high?
The 52-week high for ADMA is $20.46 and the 52-week low is $7.21. The stock is currently 50.4% below its high.